At the time of writing, Pacira BioSciences Inc [PCRX] stock is trading at $26.13, up 0.54%. An important factor to consider is whether the stock is rising or falling in short-term value. The PCRX shares have gain 4.56% over the last week, with a monthly amount glided 20.92%, and seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Pacira BioSciences Inc [NASDAQ: PCRX] stock has seen the most recent analyst activity on July 25, 2025, when Truist upgraded its rating to a Buy but kept the price target unchanged to $30 for it. Previously, Truist upgraded its rating to Hold on January 30, 2025, and elevated its price target to $25. On August 13, 2024, downgrade downgraded it’s rating to Sell and revised its price target to $8 on the stock. RBC Capital Mkts downgraded its rating to a Sector Perform and decreased its price target to $14 on August 12, 2024. Raymond James downgraded its rating to a Mkt Perform. Piper Sandler downgraded its rating to Neutral for this stock on August 12, 2024, and downed its price target to $11. In a note dated August 12, 2024, JP Morgan downgraded an Underweight rating on this stock and revised its target price from $45 to $10.
For the past year, the stock price of Pacira BioSciences Inc fluctuated between $12.61 and $27.64. Currently, Wall Street analysts expect the stock to reach $36 within the next 12 months. Pacira BioSciences Inc [NASDAQ: PCRX] shares were valued at $26.13 at the most recent close of the market. An investor can expect a potential return of 37.77% based on the average PCRX price forecast.
Analyzing the PCRX fundamentals
According to Pacira BioSciences Inc [NASDAQ:PCRX], the company’s sales were 705.85M for trailing twelve months, which represents an 1.73% jump. Gross Profit Margin for this corporation currently stands at 0.78% with Operating Profit Margin at -0.15%, Pretax Profit Margin comes in at -0.15%, and Net Profit Margin reading is -0.18%. To continue investigating profitability, this company’s Return on Assets is posted at -0.08, Equity is -0.17 and Total Capital is -0.09. An extended analysis of the company’s primary financial structure reveals a debt-to-equity ratio of0.83.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 25.77 points at the first support level, and at 25.41 for the second support level. However, for the 1st resistance point, the stock is sitting at 26.69, and for the 2nd resistance point, it is at 27.26.
Ratios To Look Out For
It is important to note that Pacira BioSciences Inc [NASDAQ:PCRX] has a current ratio of 2.38. On the other hand, the Quick Ratio is 1.91, and the Cash Ratio is 0.96. Considering the valuation of this stock, the price to sales ratio is 1.66, the price to book ratio is 1.55.
Transactions by insiders
Recent insider trading involved BIGAL MARCELO, Director, that happened on Aug 07 ’25 when 4912.0 shares were sold. Director, BIGAL MARCELO completed a deal on Aug 07 ’25 to buy 4912.0 shares. Meanwhile, Senior Vice President, Finance RIKER LAUREN sold 5578.0 shares on Jun 04 ’25.
